Ranitidine Export Market Intelligence: India's 248 Suppliers Shipping to 104 Countries — TransData Nexus 2026

Q: Who are the top ranitidine exporters from India?

The top ranitidine exporters from India are: 1. COMBITIC GLOBAL CAPLET PRIVATE LIMITED — $2.7M (21.4% market share); 2. EMCURE PHARMACEUTICALS LIMITED — $2.2M (17.5% market share); 3. LINCOLN PHARMACEUTICALS LTD — $910.5K (7.2% market share); 4. CADILA PHARMACEUTICALS LIMITED — $571.5K (4.5% market share); 5. AGILE MEDLINK — $449.7K (3.6% market share). Together they account for 54.2% of India's total ranitidine export value.

Q: What is the total export value of ranitidine from India?

The total export value of ranitidine from India is $12.6M USD, recorded across 1,996 shipment transactions from 248 active exporters to 104 destination countries. The average shipment value is $6.3K.

Q: Which countries import ranitidine from India?

India exports ranitidine to 104 countries worldwide. The top importing countries are: UZBEKISTAN (20.7% share, $2.6M), CANADA (19.3% share, $2.4M), MYANMAR (17.1% share, $2.2M), PERU (4.7% share, $592.5K), SRI LANKA (3.5% share, $444.1K). These five markets account for 65.4% of total export value.

Q: What is the HS code for ranitidine exports from India?

The primary HS code for ranitidine exports from India is 30049033. This 8-digit classification falls under Chapter 30 (pharmaceutical products) of the Harmonized System and is used by Indian Customs (DGFT) for tracking and reporting pharmaceutical trade flows.

Q: What is the average price of ranitidine exports from India?

The average unit price for ranitidine exports from India is $1.61 USD per unit, with prices ranging from $0.01 to $189.24 depending on formulation, packaging, and order volume. The total market is valued at $12.6M across 1,996 shipments.

Q: Which ports handle ranitidine exports from India?

The primary ports for ranitidine exports from India are SAHAR AIR CARGO ACC (INBOM4) (17.3% of shipments), SAHAR AIR (12.2% of shipments), DELHI AIR CARGO ACC (INDEL4) (11.6% of shipments), NHAVA SHEVA SEA (INNSA1) (7.8% of shipments), DELHI AIR (7.2% of shipments). These ports have dedicated pharmaceutical cargo infrastructure ensuring cold-chain and regulatory compliance during transit.

Q: Why is India a leading exporter of ranitidine?

India is one of the world's leading exporters of ranitidine due to its large base of 248 WHO-GMP and US FDA approved manufacturers, significantly lower production costs compared to Western markets, well-established API (Active Pharmaceutical Ingredient) supply chains, and strong government support for pharmaceutical exports through the Pharmaceuticals Export Promotion Council (Pharmexcil). India exports ranitidine to 104 countries, demonstrating 53% global market coverage.

Q: What certifications do Indian ranitidine exporters need?

Indian ranitidine exporters typically require WHO-GMP (Good Manufacturing Practice) certification for most regulated markets, US FDA approval for exports to the United States, EU GMP certification for European markets, and country-specific regulatory approvals for markets in Africa, Asia, and Latin America. Additional certifications may include ISO 9001, Schedule M compliance under Indian drug laws, and Free Sale Certificates issued by the Central Drugs Standard Control Organization (CDSCO).

Q: How many buyers import ranitidine from India?

There are 533 registered buyers importing ranitidine from India, spread across 104 countries. The repeat buyer rate is 47.5%, indicating strong long-term trade relationships and consistent product quality.

Q: What is the market share of the top ranitidine supplier from India?

COMBITIC GLOBAL CAPLET PRIVATE LIMITED is the leading ranitidine exporter from India with a market share of 21.4% and total export value of $2.7M across 68 shipments. The top 5 suppliers together control 54.2% of total export value.

Suresh Sormare

Ranitidine

India Pharmaceutical Trade Intelligence

$12.6M248 Suppliers104 CountriesHS 30049033

ExportsIndia → UZBEKISTAN20.7%India → CANADA19.3%

ImportsSINGAPORE → India$534

#1 Supplier: COMBITIC GLOBAL #1 Buyer: OOO SMARTPHARMO

Ranitidine Export Analysis | India Pharmaceutical Trade Intelligence | TransData Nexus

How India Exports Ranitidine to the World

Between 2022 and 2026, India exported $12.6M worth of ranitidine across 1,996 verified shipments to 104 countries — covering 53% of world markets in the Gastrointestinal segment. The largest destination is UZBEKISTAN (20.7%). COMBITIC GLOBAL CAPLET PRIVATE LIMITED leads with a 21.4% share. All figures are drawn from Indian Customs (DGFT) shipping bill records spanning four years of trade activity.

Source: Indian Customs (DGFT)·Published March 2026·Updated March 2026·

Ranitidine export data from India — top exporters, importing countries, pricing and trade statistics compiled by TransData Nexus — Ranitidine export data snapshot — $12.6M · 248 exporters · 104 countriesTransData Nexus · Indian Customs Data

Top Ranitidine Exporters from India

248 active exporters · Ranked by export value

View all 248 →

Top Ranitidine Exporters from India — Ranked by Export Value
#	Supplier Name	Export Value (USD)	Shipments	Countries	Market Share
1	COMBITIC GLOBAL CAPLET PRIVATE LIMITED	$2.7M	68	3	21.4%
2	EMCURE PHARMACEUTICALS LIMITED

Top Countries Importing Ranitidine from India

104 destination markets · Ranked by import value

All 104 countries →

Top Countries Importing Ranitidine from India — Ranked by Import Value
#	Country	Import Value (USD)	Market Share
1	UZBEKISTAN	$2.6M	20.7%
2	CANADA	$2.4M	19.3%
3	MYANMAR	$2.2M	17.1%
4	PERU	$592.5K	4.7%
5	SRI LANKA	$444.1K	3.5%
6	GUATEMALA	$417.1K	3.3%
7	NIGERIA	$405.5K	3.2%
8	PHILIPPINES	$334.4K	2.7%
9	AUSTRALIA	$324.0K	2.6%
10	DOMINICAN REPUBLIC	$311.8K	2.5%

UZBEKISTAN is India's largest ranitidine export destination, absorbing 20.7% of total exports worth $2.6M. The top 5 importing countries — UZBEKISTAN, CANADA, MYANMAR, PERU, SRI LANKA — together account for 65.4% of India's total ranitidine export value. The remaining 99 destination countries collectively receive the other 34.6%, indicating a well-diversified global distribution network spanning all major continents.

Who Supplies Ranitidine to India?

1 origin countries · Total import value: $534

India imports ranitidine from 1 countries with a combined import value of $534. The largest supplier is SINGAPORE ($534, 5 shipments), followed by . All values are from Indian Customs (DGFT) import records.

Countries Supplying Ranitidine to India — Ranked by Import Value
#	Origin Country	Import Value (USD)	Shipments	Share
1	SINGAPORE	$534	5	100.0%

SINGAPORE is the largest supplier of ranitidine to India, accounting for 100.0% of total import value. Click any country to see detailed supplier and buyer data for that import corridor.

Regulatory Landscape — Ranitidine

Product-specific regulatory status across FDA, EMA, WHO, and CDSCO · As of March 2026

1FDA & US Market Regulatory Status

Ranitidine has been a widely used medication in the United States, with numerous Abbreviated New Drug Applications (ANDAs) approved by the FDA. For instance, Geneva Pharmaceuticals received approval for ANDA #074467 on August 29, 1997, and Glaxo Wellcome Inc. obtained approval for NDA #020745 on February 26, 1998.

However, in April 2020, the FDA requested the removal of all ranitidine products from the U.S. market due to the detection of N-nitrosodimethylamine (NDMA), a probable human carcinogen, in these products. This action led to a significant regulatory shift, impacting the 248 active Indian exporters supplying ranitidine to the U.S. market. The regulatory pathway for re-entry into the U.S. market now requires comprehensive data demonstrating the absence of NDMA impurities and adherence to stringent quality standards.

2EU & UK Regulatory Framework

In the European Union, the European Medicines Agency (EMA) initiated a review of ranitidine medicines in September 2019 following the detection of NDMA impurities. By April 2020, the EMA's Committee for Medicinal Products for Human Use (CHMP) recommended the suspension of all ranitidine medicines in the EU. This suspension was confirmed in November 2020, leading to the withdrawal of marketing authorizations across member states. (ema.europa.eu)

Similarly, the UK's Medicines and Healthcare products Regulatory Agency (MHRA) issued a supply disruption alert in October 2019, instructing manufacturers to quarantine all ranitidine products due to NDMA contamination concerns. This action effectively removed ranitidine from the UK market, aligning with the EU's precautionary measures. (cas.mhra.gov.uk)

3WHO Essential Medicines & Global Standards

Ranitidine was included in the World Health Organization's (WHO) Model List of Essential Medicines, reflecting its importance in treating gastrointestinal conditions. However, following the detection of NDMA impurities, the WHO issued safety alerts regarding ranitidine, advising regulatory authorities to assess the risk and consider appropriate actions. (who.int)

Pharmacopoeial standards, including those from the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), have historically included monographs for ranitidine. In light of contamination concerns, these standards are under review to ensure the quality and safety of ranitidine products.

4India Regulatory Classification

In India, ranitidine is classified as a Schedule H drug under the Drugs and Cosmetics Act, requiring a prescription for dispensing. The Central Drugs Standard Control Organization (CDSCO) oversees its regulation. Following global concerns about NDMA impurities, the CDSCO issued advisories to pharmaceutical companies to assess and ensure the quality of ranitidine products.

The National Pharmaceutical Pricing Authority (NPPA) had set ceiling prices for ranitidine formulations under the Drug Price Control Order (DPCO). However, due to safety concerns and subsequent market withdrawals, these pricing controls are subject to review. Export No Objection Certificates (NOCs) are required for the export of ranitidine, ensuring compliance with both domestic and international regulatory standards.

5Patent & Exclusivity Status

The primary patents for ranitidine have long expired, leading to a competitive generic market. However, the detection of NDMA impurities has led to market withdrawals and increased scrutiny, affecting the competitive landscape. Manufacturers must now demonstrate compliance with updated safety and quality standards to re-enter markets.

6Recent Industry Developments

In April 2020, the FDA requested the removal of all ranitidine products from the U.S. market due to NDMA contamination, leading to a significant shift in the regulatory landscape. (ema.europa.eu)

In November 2020, the EMA confirmed the suspension of all ranitidine medicines in the EU, reinforcing the global trend of regulatory actions against ranitidine due to safety concerns. (ema.europa.eu)

In October 2019, the UK's MHRA issued a supply disruption alert, instructing manufacturers to quarantine all ranitidine products, effectively removing them from the UK market. (cas.mhra.gov.uk)

In April 2020, the WHO issued an information note updating on nitrosamine impurities, including those found in ranitidine, advising regulatory authorities to assess risks and consider appropriate actions. (tdr.who.int)

These developments underscore the heightened regulatory scrutiny and the need for manufacturers to ensure the safety and quality of ranitidine products in compliance with international standards.

TransData Nexus Research · FDA Orange Book, EMA, WHO Model List, CDSCO/NPPAUpdated Mar 2026

Get Complete Export Intelligence Report

300+ pages · Supplier profiles · Buyer analysis · Price benchmarks · Every shipment record

Free

Supply Chain Risk Assessment — Ranitidine

API sourcing, concentration risk, storage requirements, and current alerts

MEDIUM RISK

1API Sourcing & Raw Material Dependency

Ranitidine's production heavily relies on Active Pharmaceutical Ingredients (APIs) and Key Starting Materials (KSMs), with a significant portion sourced from China. China controls approximately 70–80% of the global KSM supply and 60–70% of intermediates, making it a dominant player in the pharmaceutical raw material market. This dependency exposes the supply chain to risks associated with China's regulatory changes and environmental policies. For instance, over the past five years, numerous Chinese API manufacturers have been shut down due to non-compliance with pollution norms, leading to supply disruptions and cost escalations.

In response to these challenges, India has initiated measures to reduce its reliance on Chinese imports. The Production Linked Incentive (PLI) scheme, launched in 2020, aims to bolster domestic API manufacturing by providing financial incentives to local producers. By November 2024, two greenfield plants were inaugurated under this scheme to manufacture critical molecules used in common antibiotics, marking a significant step towards self-reliance. However, the effectiveness of these initiatives in mitigating supply chain risks for ranitidine remains to be fully realized.

2Supplier Concentration & Single-Source Risk

Our proprietary trade data indicates that the top five Indian exporters of ranitidine account for 54.2% of the total export value, with COMBITIC GLOBAL CAPLET PRIVATE LIMITED leading at a 21.4% share. This concentration suggests a moderate risk of supply disruption if any of these key suppliers face operational challenges. The PLI scheme's focus on enhancing domestic API production is a strategic move to diversify the supplier base and reduce single-source dependency. However, the transition to a more diversified supply chain will require time and sustained effort.

Access Complete Ranitidine Trade Intelligence

Shipment-level records, verified supplier contacts, buyer histories, and pricing analytics for all 1,996 transactions across 104 markets.

Request Demo View Pricing

Frequently Asked Questions — Ranitidine Exports from India

Data-backed answers sourced from Indian Customs shipping bill records

Who are the top ranitidine exporters from India?

The leading ranitidine exporters from India are COMBITIC GLOBAL CAPLET PRIVATE LIMITED, EMCURE PHARMACEUTICALS LIMITED, LINCOLN PHARMACEUTICALS LTD, and 12 others. COMBITIC GLOBAL CAPLET PRIVATE LIMITED leads with 21.4% market share ($2.7M). The top 5 suppliers together control 54.2% of total export value.

What is the total export value of ranitidine from India?

The total export value of ranitidine from India is $12.6M, recorded across 1,996 shipments from 248 active exporters to 104 countries. The average shipment value is $6.3K.

Which countries import ranitidine from India?

India exports ranitidine to 104 countries. The top importing countries are UZBEKISTAN (20.7%), CANADA (19.3%), MYANMAR (17.1%), PERU (4.7%), SRI LANKA (3.5%), which together account for 65.4% of total export value.

What is the HS code for ranitidine exports from India?

The primary HS code for ranitidine exports from India is 30049033. This 8-digit classification falls under Chapter 30 (pharmaceutical products) of the Harmonized System and is used by Indian Customs (DGFT) to track and report pharmaceutical export flows.

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Ranitidine

Ranitidine

How India Exports Ranitidine to the World

Top Ranitidine Exporters from India

Top Countries Importing Ranitidine from India

Who Supplies Ranitidine to India?

Quick Facts

Related Gastrointestinal

Related Analysis

Need Details?

Regulatory Landscape — Ranitidine

1FDA & US Market Regulatory Status

2EU & UK Regulatory Framework

3WHO Essential Medicines & Global Standards

4India Regulatory Classification

5Patent & Exclusivity Status

6Recent Industry Developments

Supply Chain Risk Assessment — Ranitidine

1API Sourcing & Raw Material Dependency

2Supplier Concentration & Single-Source Risk

Access Complete Ranitidine Trade Intelligence

Frequently Asked Questions — Ranitidine Exports from India

Who are the top ranitidine exporters from India?

What is the total export value of ranitidine from India?

Which countries import ranitidine from India?

What is the HS code for ranitidine exports from India?

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Primary Data Source

3Geopolitical & Shipping Disruptions

4Risk Mitigation Recommendations

What is the average price of ranitidine exports from India?

Which ports handle ranitidine exports from India?

Why is India a leading exporter of ranitidine?

What certifications do Indian ranitidine exporters need?

How many buyers import ranitidine from India?

What is the market share of the top ranitidine exporter from India?

Analysis Methodology